Jonsson Comprehensive Cancer Center: Leukemia trials
The registry lists 21 Leukemia studies with Jonsson Comprehensive Cancer Center as lead sponsor. 1 are open to participants now and 0 have results posted.
Phase 1 8Phase 2 9Phase 3 4No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)RecruitingNCT06810778Phase 1/2
- Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid LeukemiaWithdrawnNCT05720988Phase 1
- CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid LeukemiaTerminatedNCT03904251Phase 1
- CPX-351 Plus Enasidenib for Relapsed AMLActive, not recruitingNCT03825796Phase 2
- Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic LymphomaTerminatedNCT02928510
- Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic LeukemiaCompletedNCT00345826Phase 1
- PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL TherapyStatus unknownNCT00335868Phase 2
- Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for CancerCompletedNCT00255749Phase 2
- Eculizumab in Treating Patients With Paroxysmal Nocturnal HemoglobinuriaCompletedNCT00112983Phase 3
- BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib MesylateStatus unknownNCT00112775Phase 2
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib MesylateCompletedNCT00100997Phase 1
- Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid LeukemiaStatus unknownNCT00093587Not applicable
- Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for CancerCompletedNCT00070382Phase 3
- BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib MesylateCompletedNCT00064233Phase 1
- Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and NeutropeniaStatus unknownNCT00020865Phase 3
- STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic LeukemiaCompletedNCT00015860Phase 1/2
- Monoclonal Antibody in Treating Patients With Acute Myelogenous LeukemiaStatus unknownNCT00006084Phase 2
- Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a CatheterCompletedNCT00006083Phase 3
- Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid LeukemiaWithdrawnNCT00004878Phase 2
- Growth Factor to Prevent Oral Mucositis in Patients With Hematologic CancerCompletedNCT00004132Phase 2
- Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic CancerWithdrawnNCT00004114Phase 1